Zydus Lifesciences Limited has informed the Exchange regarding Change in Director(s) of the company.
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zydus Lifesciences shareholders, at the Annual General Meeting held on August 12, 2025, approved the re-appointment of Mr. Ganesh N. Nayak (DIN: 00017481) as Executive Director of the company. He has been re-appointed for a further period of five years, from July 12, 2025 to July 11, 2030. A special resolution was required because Mr. Nayak has already crossed 70 years of age. He will be entitled to a remuneration of Rs. 3 million per month (Rs. 36 million per annum), inclusive of the company's contribution to the Provident Fund. Mr. Nayak joined the Zydus Group in 1977 and brings over 48 years of experience, having played a key role in the company's M&A deals and global expansion. He is not debarred from holding the office of director by any regulatory authority.
This is a routine re-appointment of an existing executive director, signalling leadership continuity with no disruption for shareholders. The cost impact from his remuneration is marginal relative to the company's overall scale, so the event is largely neutral for the stock.